Eventually, several laboratory studies showed a direct and statistically significant relationship between ornithine decarboxylase (ODC1) and MYCN gene expression, which led to the exploration of newer avenues for the use of DFMO - especially in neuroblastoma. The gene discussed is MYCN; the disease is neuroblastoma.